Symbicort vs Daliresp
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Symbicort | US Daliresp | |
|---|---|---|
| Generic name | budesonide/formoterol | roflumilast |
| Drug class | ICS/LABA Inhaler | PDE4 Inhibitor (Oral) |
| Treats | Asthma, COPD | Chronic obstructive pulmonary disease (COPD) |
| Category | Respiratory | Respiratory |
| Manufacturer | AstraZeneca | AstraZeneca |
| Year approved | 2006 | 2011 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $120M | — |
| Common side effects | Throat irritation, Oral thrush, Hoarseness, Headache | Diarrhea, Weight loss, Nausea, Headache |
Symbicort
Frequently asked questions
Is Symbicort or Daliresp better?
Neither is universally "better." Symbicort (budesonide/formoterol) and Daliresp (roflumilast) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Symbicort and Daliresp?
Symbicort is a ICS/LABA Inhaler made by AstraZeneca, while Daliresp is a PDE4 Inhibitor (Oral) made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Symbicort has the larger estimated TV advertising budget of the two.